Accelerating revenue, partnerships, and strategic market access in Europe
A US-based nonprofit and global authority in regenerative medicine, with a decades of experience advancing liver biology and organ procurement. As part of a strategic diversification initiative, the client launched a life sciences division to supply high-quality human cells and tissues to biopharma, CROs, and academic research institutions. With growing interest from European markets and an ambition to scale internationally, the client turned to Novoptim to lead their market entry and revenue acceleration across the EU region.
To support its entry into the European market, the client needed to build a qualified sales pipeline, generate early revenue, and establish strategic partnerships, all from its U.S. headquarters. Without a local presence, engaging the right stakeholders and navigating varying procurement practices across countries presented a logistical and operational challenge. The objective was not only to initiate commercial activity, but to do so in a way that aligned with the organization’s growth strategy, operational capacity, and nonprofit mission. Success depended on accelerating deal conversion while building a scalable and repeatable business development model, without the time and investment required to establish a full in-house team in Europe.
Novoptim deployed its Growth Accelerator service, an integrated commercial model combining marketing, inside sales and sales activities. Working closely with the client’s leadership team, we co-developed a tailored go-to-market strategy focused on the most relevant applications, high-priority customer segments, and the specific dynamics of the European market. Our cross-functional team managed the entire sales cycle, from lead identification and qualification to negotiation and closing, while ensuring all actions remained aligned with the client’s internal processes and long-term growth plans. As the project progressed, messaging and targeting were continuously refined based on direct feedback from pharmaceutical companies, biotech firms and academic labs. This iterative approach helped sharpen the value proposition, build credibility with key decision-makers, and streamline the purchasing experience, a critical factor in a space where validation cycles are long and trust is key.
Over the course of the engagement, Novoptim built a strong and diverse commercial pipeline, including leading pharmaceutical companies, CROs, biotech firms, and academic labs. Sales targets were exceeded within the first year, and multiple deals were successfully closed, validating the commercial model. Beyond near-term results, Novoptim helped establish a long-term business development structure across Europe, laying the foundation for sustained commercial growth. The initiative contributed to an impressive 114% compound annual growth rate over four years, reinforcing the client as a leading partner in regenerative medicine.
Whether you’re entering the market or scaling your presence, we’re here to turn your innovation into commercial success.
